ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Carcinoma
Neoplasm Metastasis

Non-Small-Cell Lung Cancer trials near Durham, NC, USA:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Chapel Hill, North Carolina, United States and 83 other locations

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC)....

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: Nab-Paclitaxel
Drug: Cisplatin

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Durham, North Carolina, United States and 126 other locations

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mort...

Enrolling
Non-Small Cell Lung Cancer
Drug: Carboplatin
Drug: Livmoniplimab

Phase 2, Phase 3

AbbVie
AbbVie

Greensboro, North Carolina, United States and 60 other locations

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Durvalumab
Procedure: Surgery

Phase 3

AstraZeneca
AstraZeneca

Durham, North Carolina, United States and 230 other locations

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)

This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combina...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Oleclumab
Drug: Durvalumab

Phase 3

AstraZeneca
AstraZeneca

Greensboro, North Carolina, United States and 202 other locations

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) wit...

Active, not recruiting
Advanced Non-Small Cell Squamous Lung Cancer
Advanced Lung Carcinoma
Drug: silevertinib (BDTX-1535) monotherapy

Phase 1, Phase 2

Black Diamond Therapeutics

Chapel Hill, North Carolina, United States and 28 other locations

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alter...

Enrolling
NSCLC
Drug: REGN5093

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Durham, North Carolina, United States and 32 other locations

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (Krascendo 1)

with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC)....

Active, not recruiting
KRAS G12C Lung Cancer
Non-Small Cell Lung Cancer
Drug: Sotorasib
Drug: Divarasib

Phase 3

Roche
Roche

Chapel Hill, North Carolina, United States of America and 200 other locations

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (RAMP204)

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small...

Active, not recruiting
Metastatic Cancer
Advanced Cancer
Drug: avutometinib (VS-6766) and adagrasib

Phase 1, Phase 2

Verastem

Chapel Hill, North Carolina, United States of America and 7 other locations

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (...

Active, not recruiting
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Drug: Placebo
Drug: Docetaxel

Phase 3

AstraZeneca
AstraZeneca

Durham, North Carolina, United States and 196 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems